Should I buy or sell Curis stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRIS shares. View CRIS analyst ratings or view top-rated stocks .

What is Curis' stock price target for 2024?

3 Wall Street analysts have issued 1 year price objectives for Curis' stock. Their CRIS share price targets range from $26.00 to $60.00. On average, they anticipate the company's share price to reach $37.33 in the next twelve months. This suggests a possible upside of 258.6% from the stock's current price. View analysts price targets for CRIS or view top-rated stocks among Wall Street analysts .

How have CRIS shares performed in 2024?

Curis' stock was trading at $12.75 at the beginning of 2024. Since then, CRIS stock has decreased by 18.4% and is now trading at $10.41. View the best growth stocks for 2024 here .

When is Curis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CRIS earnings forecast .

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings results on Thursday, February, 8th. The biotechnology company reported ($2.03) earnings per share for the quarter, missing analysts' consensus estimates of ($1.91) by $0.12. The biotechnology company had revenue of $2.70 million for the quarter, compared to analysts' expectations of $2.95 million. Curis had a negative net margin of 473.04% and a negative trailing twelve-month return on equity of 153.93%. During the same period in the previous year, the business earned ($2.40) earnings per share.

When did Curis' stock split?

Curis shares reverse split on the morning of Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD) , Celldex Therapeutics (CLDX) , Micron Technology (MU) , Novavax (NVAX) , CTI BioPharma (CTIC) , Nabriva Therapeutics (NBRV) , Amarin (AMRN) , Idera Pharmaceuticals (IDRA) , ImmunoGen (IMGN) and OPKO Health (OPK) .

Who are Curis' major shareholders?

Curis' stock is owned by many different retail and institutional investors. Top institutional investors include Arnhold LLC (0.28%), a16z Perennial Management L.P. (0.11%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Curis?

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CRIS

Curis (CRIS) Stock Price, News & Analysis

$10.41

-0.24 (-2.25%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $9.88
▼
$10.51
50-Day Range: $8.49
▼
$14.47
52-Week Range: $3.80
▼
$20.00

Volume: 14,700 shs
Average Volume: 47,796 shs
Market Capitalization: $61.31 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.33

Get Curis alerts:

Curis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 258.6% Upside
$37.33 Price Target
Short Interest: Healthy
0.99% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.17
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.64) to ($4.55) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.19 out of 5 stars

Medical Sector

582nd out of 922 stocks

Biological Products, Except Diagnostic Industry

97th out of 151 stocks

3.5

Analyst's Opinion

Consensus Rating
Curis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.33, Curis has a forecasted upside of 258.6% from its current price of $10.41.
Amount of Analyst Coverage
Curis has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.99% of the float of Curis has been sold short.
Short Interest Ratio / Days to Cover
Curis has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Curis has recently decreased by 40.46%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Curis does not currently pay a dividend.
Dividend Growth
Curis does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CRIS.

1.6

News and Social Media Coverage

News Sentiment
Curis has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Curis this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for CRIS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
3 people have added Curis to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Curis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.81% of the stock of Curis is held by insiders.
Percentage Held by Institutions
Only 25.41% of the stock of Curis is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Curis are expected to grow in the coming year, from ($4.64) to ($4.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Curis is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Curis is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Curis has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Curis Stock (NASDAQ:CRIS)

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with solid tumors and lymphomas; and CA-327, a pre-clinical development candidate, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma; and Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

CRIS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRIS Stock News Headlines

February 11, 2024 | americanbankingnews.com

HC Wainwright Lowers Curis (NASDAQ:CRIS) Price Target to $26.00

February 10, 2024 | msn.com

Curis Inc. Is Worried About This – Should You Be Worried Too?

February 12, 2024 | The Freeport Society (Ad)

New Trump Bombshell

I believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… If I’m right, the soul of this country will change forever…

February 9, 2024 | finance.yahoo.com

Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript

February 8, 2024 | finanznachrichten.de

Curis, Inc.: Curis Provides Fourth Quarter 2023 Business Update

February 8, 2024 | markets.businessinsider.com

Curis Inc Q4 sales decline

February 8, 2024 | finance.yahoo.com

Curis Provides Fourth Quarter 2023 Business Update

February 7, 2024 | benzinga.com

Curis's Earnings: A Preview

February 12, 2024 | The Freeport Society (Ad)

Biden Out, _______ In?

A new poll shows that two-thirds of Democrats want Biden to drop out of the 2024 race. The truth will shock you.

February 7, 2024 | americanbankingnews.com

Curis (CRIS) Scheduled to Post Earnings on Thursday

February 1, 2024 | finance.yahoo.com

Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

January 22, 2024 | finance.yahoo.com

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

December 18, 2023 | finance.yahoo.com

Curis, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For Excitement

December 12, 2023 | markets.businessinsider.com

Buy Rating on Curis Backed by Promising Clinical Trials and Strategic Expansion

December 12, 2023 | finance.yahoo.com

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

December 11, 2023 | finance.yahoo.com

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

December 6, 2023 | markets.businessinsider.com

Positive Buy Rating for Curis Stock Driven by Emavusertib’s Clinical Promise and Revenue Potential

December 6, 2023 | finance.yahoo.com

Curis Announces Three Presentations at ASH

December 5, 2023 | markets.businessinsider.com

Curis Inks Deal With Florida University For Emavusertib/Pembrolizumab Combination Study In Melanoma

December 5, 2023 | finance.yahoo.com

Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

November 18, 2023 | morningstar.com

Curis Inc CRIS

November 18, 2023 | msn.com

Truist Securities Initiates Coverage of Curis (CRIS) with Buy Recommendation

November 17, 2023 | msn.com

Curis, Emergent Biosolutions among healthcare movers

November 17, 2023 | msn.com

Curis’s stock rises as analysts see ‘the next Pharmacyclics’

November 3, 2023 | finance.yahoo.com

Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript

November 3, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Curis (CRIS), Trevi Therapeutics (TRVI) and Prothena (PRTA)

November 3, 2023 | finance.yahoo.com

Curis Inc (CRIS) Reports Q3 2023 Financial Results: Net Loss Decreases Year-Over-Year

See More Headlines

Receive CRIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/08/2024
Today: 2/12/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:CRIS
CUSIP: 23126910
CIK: 1108205
Web: www.curis.com
Phone: (617) 503-6500
Fax: 617-503-6501
Employees: 51
Year Founded: 2000

Price Target and Rating

Average Stock Price Target: $37.33
High Stock Price Target: $60.00
Low Stock Price Target: $26.00
Potential Upside/Downside: +258.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-56,670,000.00
Net Margins: -473.04%
Pretax Margin: -460.45%
Return on Equity: -153.93%
Return on Assets: -52.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.36
Quick Ratio: 5.36

Sales & Book Value

Annual Sales: $10.02 million
Price / Sales: 6.12
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.66 per share
Price / Book: 1.08

Miscellaneous

Outstanding Shares: 5,890,000
Free Float: 5,610,000
Market Cap: $61.31 million
Optionable: Optionable
Beta: 3.78

Social Links

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. James E. Dentzer (Age 57)
President, CEO & Director
Comp: $912.29k
Ms. Diantha Duvall CPA (Age 52)
M.B.A., CFO, Treasurer, Assistant Secretary, Principal Financial Officer & Principal Accounting Officer
Comp: $588.95k
Mr. Mark W. Noel (Age 65)
Vice President of Technology Management & Intellectual Property
Comp: $279.28k
Ms. Elif McDonald
VP of Investor Relations & Corporate Communications
Dr. Reinhard Wilhelm von Roemeling M.D.
Senior Vice President of Clinical Development
Dr. Jonathan B. Zung Ph.D. (Age 59)
Chief Development Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CRIS Stock Analysis - Frequently Asked Questions

Should I buy or sell Curis stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRIS shares.
View CRIS analyst ratings or view top-rated stocks.
What is Curis' stock price target for 2024?: 3 Wall Street analysts have issued 1 year price objectives for Curis' stock. Their CRIS share price targets range from $26.00 to $60.00. On average, they anticipate the company's share price to reach $37.33 in the next twelve months. This suggests a possible upside of 258.6% from the stock's current price.
View analysts price targets for CRIS or view top-rated stocks among Wall Street analysts.
How have CRIS shares performed in 2024?: Curis' stock was trading at $12.75 at the beginning of 2024. Since then, CRIS stock has decreased by 18.4% and is now trading at $10.41.
View the best growth stocks for 2024 here.
When is Curis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CRIS earnings forecast.
How were Curis' earnings last quarter?: Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings results on Thursday, February, 8th. The biotechnology company reported ($2.03) earnings per share for the quarter, missing analysts' consensus estimates of ($1.91) by $0.12. The biotechnology company had revenue of $2.70 million for the quarter, compared to analysts' expectations of $2.95 million. Curis had a negative net margin of 473.04% and a negative trailing twelve-month return on equity of 153.93%. During the same period in the previous year, the business earned ($2.40) earnings per share.

When did Curis' stock split?: Curis shares reverse split on the morning of Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Curis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).
Who are Curis' major shareholders?: Curis' stock is owned by many different retail and institutional investors. Top institutional investors include Arnhold LLC (0.28%), a16z Perennial Management L.P. (0.11%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Curis?: Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRIS) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial